



uniQure Appoints Maria E. Cantor as Senior Vice President, Investor Relations & Communications

June 27, 2016

AMSTERDAM, the Netherlands, June 27, 2016 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Maria E. Cantor as Senior Vice President, Investor Relations and Communications. Ms. Cantor joins the Company from ARAD Pharmaceuticals, Inc. where she most recently held the role of Senior Vice President, Corporate Affairs. With over 20 years of experience in communications in the biotech and healthcare industry, she will lead external communications for uniQure, including investor relations, media and digital communications, and corporate image and branding. She will serve as a member of the Company's senior management team and will be based in its Leuven, Massachusetts facility. "Maria is a highly regarded leader in defining the long-term value proposition of some of the most successful companies in our industry, and she is an exciting addition to the senior management team at uniQure," said Dan Soltes, Chief Executive Officer of uniQure. "Her substantial experience in developing integrated, global and strategic communication programs will be very valuable as we continue to advance our broad pipeline of gene therapies through clinical development and towards commercialization."

"Being a part of shaping the future of gene therapy and helping to bring these potentially transformational therapies to patients around the world is a unique opportunity," said Ms. Cantor. "I look forward to working with the uniQure team in the U.S. and in Europe to support the next stage of the Company's development and to help build shareholder value."

At ARAD Pharmaceuticals, Ms. Cantor was a member of the senior management team and had been responsible for investor relations and corporate communications for the company since 2008. She played an active role in several successful financing rounds for ARAD and led the communications program for the clinical development, regulatory approval and product launch of the company's first cancer therapeutic, *luspatercept*, (formerly approved in both the U.S. and Europe. Prior to joining ARAD, she held the position of Senior Director, Corporate Communications at Genzyme, where she was involved in all aspects of corporate and product communications from 2001 to 2008. In addition to her extensive expertise as a communications leader in biotechnology companies, Ms. Cantor also held senior communications positions within the healthcare industry including Director, Marketing and Public Relations at the St. Elizabeth Medical Center in Boston, and as Director, Marketing and Communications at Quinn Healthcare Inc. in Manchester, New Hampshire.

Ms. Cantor holds a Master of Science in Communications Management from Syracuse University, S.I. Newhouse School of Public Communications in Syracuse, New York and a Bachelor of Science in Mass Communication/Broadcast Journalism from Emerson College in Boston.

About uniQure

uniQure is delivering on the promise of gene therapy — single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, inborn metabolic and cardiovascular diseases. www.uniQure.com

uniQure Forward-Looking Statement

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "seek forward to," "may," "might," "potential," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the development of our gene therapy product candidates, the success of our collaborations and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with collaboration arrangements, our and our collaborative clinical development activities, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's 2015 Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2016. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

CONTACT: uniQure | Maria Cantor & Eva Muller Direct | +31 20 240 6103 (Netherlands) | +1 202 240 8000 or +1 339 970 7000 m.cantor@uniQure.com or e.muller@uniQure.com Media inquiries | Gretchen Schweitzer or Stephanie Key MacDougall Biomedical Communications Direct | +49 172 861 8540 or +49 170 9711662 (Netherlands) | +49 89 2424 2494 or +1 781 235 3060 gschweitzer@mediacomm.com